WO2007047512A3 - Inhibition of pax2 by defb1 induction as a therapy for cancer - Google Patents

Inhibition of pax2 by defb1 induction as a therapy for cancer Download PDF

Info

Publication number
WO2007047512A3
WO2007047512A3 PCT/US2006/040215 US2006040215W WO2007047512A3 WO 2007047512 A3 WO2007047512 A3 WO 2007047512A3 US 2006040215 W US2006040215 W US 2006040215W WO 2007047512 A3 WO2007047512 A3 WO 2007047512A3
Authority
WO
WIPO (PCT)
Prior art keywords
pax2
defbl
cancer
subject
inhibition
Prior art date
Application number
PCT/US2006/040215
Other languages
French (fr)
Other versions
WO2007047512A2 (en
Inventor
Carlton D Donald
Original Assignee
Musc Found For Res Dev
Carlton D Donald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/090,191 priority Critical patent/US7964577B2/en
Priority to CA002625891A priority patent/CA2625891A1/en
Priority to AU2006304321A priority patent/AU2006304321B2/en
Priority to EP06816925A priority patent/EP1934331A4/en
Application filed by Musc Found For Res Dev, Carlton D Donald filed Critical Musc Found For Res Dev
Publication of WO2007047512A2 publication Critical patent/WO2007047512A2/en
Publication of WO2007047512A3 publication Critical patent/WO2007047512A3/en
Priority to US12/708,294 priority patent/US8080534B2/en
Priority to US13/005,579 priority patent/US8735365B2/en
Priority to US13/005,568 priority patent/US8318692B2/en
Priority to US13/009,594 priority patent/US20110177075A1/en
Priority to US13/009,970 priority patent/US20110177101A1/en
Priority to US13/010,867 priority patent/US8431546B2/en
Priority to US13/050,604 priority patent/US8394780B2/en
Priority to US13/051,644 priority patent/US20110212089A1/en
Priority to US13/072,311 priority patent/US20110206666A1/en
Priority to US13/072,202 priority patent/US20110206665A1/en
Priority to US13/098,061 priority patent/US20110229468A1/en
Priority to US13/098,033 priority patent/US20110229467A1/en
Priority to US13/114,824 priority patent/US8461101B2/en
Priority to US13/114,811 priority patent/US8633149B2/en
Priority to US13/116,752 priority patent/US20110243937A1/en
Priority to US13/116,722 priority patent/US8653021B2/en
Priority to US13/310,930 priority patent/US20120071347A1/en
Priority to US13/310,940 priority patent/US8461126B2/en
Priority to US13/912,841 priority patent/US8722643B2/en
Priority to US14/157,231 priority patent/US20140135378A1/en
Priority to US14/464,565 priority patent/US11033628B1/en
Priority to US16/573,940 priority patent/US20200085967A1/en
Priority to US17/189,525 priority patent/US20210213136A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFBl in the subject. In the method wherein the expression of DEFBl is increased, it can be increased by blocking the binding of PAX2 to the DEFBl promoter. Blocking the binding of PAX2 to the DEFBl promoter can be by administration of an oligonucleotide containing the PAX2 DNA binding site of DEFBl. This oligonucleotide can be complementary to the sequence of PAX2 that binds to the DEFBl promoter. Alternatively, the oligonucleotide can interact with the PAX2 in a way that inhibits binding to DEFBl.
PCT/US2006/040215 2005-10-14 2006-10-16 Inhibition of pax2 by defb1 induction as a therapy for cancer WO2007047512A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
US12/090,191 US7964577B2 (en) 2005-10-14 2006-10-16 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
CA002625891A CA2625891A1 (en) 2005-10-14 2006-10-16 Inhibition of pax2 by defb1 induction as a therapy for cancer
AU2006304321A AU2006304321B2 (en) 2005-10-14 2006-10-16 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
EP06816925A EP1934331A4 (en) 2005-10-14 2006-10-16 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US12/708,294 US8080534B2 (en) 2005-10-14 2010-02-18 Targeting PAX2 for the treatment of breast cancer
US13/005,579 US8735365B2 (en) 2005-10-14 2011-01-13 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US13/005,568 US8318692B2 (en) 2005-10-14 2011-01-13 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US13/009,594 US20110177075A1 (en) 2005-10-14 2011-01-19 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US13/009,970 US20110177101A1 (en) 2005-10-14 2011-01-20 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US13/010,867 US8431546B2 (en) 2005-10-14 2011-01-21 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US13/050,604 US8394780B2 (en) 2005-10-14 2011-03-17 Targeting PAX2 for the treatment of breast cancer
US13/051,644 US20110212089A1 (en) 2005-10-14 2011-03-18 Targeting pax2 for the treatment of breast cancer
US13/072,202 US20110206665A1 (en) 2005-10-14 2011-03-25 Targeting pax2 for the treatment of breast cancer
US13/072,311 US20110206666A1 (en) 2005-10-14 2011-03-25 Targeting pax2 for the treatment of breast cancer
US13/098,061 US20110229468A1 (en) 2005-10-14 2011-04-29 Targeting pax2 for the treatment of breast cancer
US13/098,033 US20110229467A1 (en) 2005-10-14 2011-04-29 Targeting pax2 for the treatment of breast cancer
US13/114,824 US8461101B2 (en) 2005-10-14 2011-05-24 Targeting PAX2 for the treatment of breast cancer
US13/114,811 US8633149B2 (en) 2005-10-14 2011-05-24 Targeting PAX2 for the treatment of breast cancer
US13/116,752 US20110243937A1 (en) 2005-10-14 2011-05-26 Targeting pax2 for the treatment of breast cancer
US13/116,722 US8653021B2 (en) 2005-10-14 2011-05-26 Targeting PAX2 for the treatment of breast cancer
US13/310,940 US8461126B2 (en) 2005-10-14 2011-12-05 Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
US13/310,930 US20120071347A1 (en) 2005-10-14 2011-12-05 Compositions and methods for monitoring and detecting cancerous conditions
US13/912,841 US8722643B2 (en) 2005-10-14 2013-06-07 Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
US14/157,231 US20140135378A1 (en) 2005-10-14 2014-01-16 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
US14/464,565 US11033628B1 (en) 2005-10-14 2014-08-20 Targeting PAX2 for the treatment of breast cancer
US16/573,940 US20200085967A1 (en) 2005-10-14 2019-09-17 Targeting pax2 for the treatment of breast cancer
US17/189,525 US20210213136A1 (en) 2005-10-14 2021-03-02 Targeting pax2 for the treatment of breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72692105P 2005-10-14 2005-10-14
US60/726,921 2005-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/546,292 Continuation-In-Part US20100029504A1 (en) 2005-10-14 2009-08-24 Detecting pax2 for the diagnosis of breast cancer

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US12/090,191 A-371-Of-International US7964577B2 (en) 2005-10-14 2006-10-16 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US12090191 A-371-Of-International 2007-04-26
US9019108A Continuation 2005-10-14 2008-09-15
US12/708,294 Continuation-In-Part US8080534B2 (en) 2005-10-14 2010-02-18 Targeting PAX2 for the treatment of breast cancer
US13/009,594 Continuation US20110177075A1 (en) 2005-10-14 2011-01-19 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US13/010,867 Continuation US8431546B2 (en) 2005-10-14 2011-01-21 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy

Publications (2)

Publication Number Publication Date
WO2007047512A2 WO2007047512A2 (en) 2007-04-26
WO2007047512A3 true WO2007047512A3 (en) 2007-06-14

Family

ID=37963139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040215 WO2007047512A2 (en) 2005-10-14 2006-10-16 Inhibition of pax2 by defb1 induction as a therapy for cancer

Country Status (5)

Country Link
US (6) US7964577B2 (en)
EP (7) EP2189522A1 (en)
AU (1) AU2006304321B2 (en)
CA (1) CA2625891A1 (en)
WO (1) WO2007047512A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
AP2009004851A0 (en) * 2007-01-16 2009-06-30 Music Foundation For Res Dev Compositions and methods for diagnosing, treating,and preventing prostate conditions
CN104726593A (en) * 2011-12-23 2015-06-24 上海吉凯基因化学技术有限公司 Human NLK (nemo-like kinase) gene related use and related drugs
CN103290016B (en) * 2013-06-21 2015-04-22 厦门大学 Branchiostoma belcheri Pax2/5/8 gene non-coding conservative element enhancer and application thereof
WO2016090169A1 (en) * 2014-12-03 2016-06-09 Seed Research And Development Llc Intracellular caspase probes for detection of apoptosis and inflammation and kits containing such probes
KR101590452B1 (en) 2015-05-20 2016-02-02 중앙대학교 산학협력단 Pharmaceutical composition for enhancing immune response and preventing or treating cancer comprising peptide DEFB124
CN109908326A (en) * 2018-09-14 2019-06-21 上海众择生物科技有限公司 People's beta-alexin 1 is promoting the application in NK cell killing activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142320A1 (en) * 1999-02-20 2002-10-03 Ogden Christopher William Diagnosis and treatment of prostate cancer
US20050095257A1 (en) * 2000-09-15 2005-05-05 Kwak Larry W. Defensin-antigen fusion proteins

Family Cites Families (378)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA678802A (en) 1964-01-28 J. Marino Frank Portable loading canopy
US1159250A (en) * 1914-05-01 1915-11-02 Frank Moulton Vaginal irrigator.
US1666684A (en) * 1926-01-15 1928-04-17 Carstens Mfg Co H Vaginal douche
US1924972A (en) * 1929-04-15 1933-08-29 Carl J Beckert Stabilized egg product
US2085733A (en) * 1935-07-15 1937-07-06 John C Bird Shaving cream
US2390921A (en) * 1943-03-23 1945-12-11 Ethel Hudson Clark Applicator for facial creams
US2524590A (en) * 1946-04-22 1950-10-03 Carsten F Boe Emulsion containing a liquefied propellant gas under pressure and method of spraying same
US2586287A (en) * 1948-12-11 1952-02-19 Colagte Palmolive Peet Company Aluminum sulfamate antiperspirant preparation
US2617754A (en) * 1949-08-29 1952-11-11 Procter & Gamble Cosmetic cream
US3062715A (en) * 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
US2767712A (en) * 1954-03-01 1956-10-23 Neil S Waterman Medicinal applicator
US3092555A (en) * 1958-04-21 1963-06-04 Roy H Horn Relatively collapsible aerosol foam compositions
US3144386A (en) * 1958-05-09 1964-08-11 Merck & Co Inc Mastitis aerosol foam
US2968628A (en) * 1958-10-17 1961-01-17 Shulton Inc Propellant composition
US3178352A (en) * 1959-02-27 1965-04-13 Erickson Roy Shaving method and composition therefor
US3141821A (en) * 1959-03-17 1964-07-21 Lehn & Fink Products Corp Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis
US3004894A (en) * 1959-04-07 1961-10-17 Upjohn Co Therapeutic composition comprising tetracycline and a dioxolane
US3142420A (en) * 1959-11-09 1964-07-28 Neotechnic Eng Ltd Metering dispenser for aerosol with fluid pressure operated piston
US3092255A (en) * 1960-02-05 1963-06-04 Robert F Hohman Sorting apparatus
US3067784A (en) * 1960-04-14 1962-12-11 Esta Medical Lab Inc Adapter connecting aerosol container valve stem to dispenser for filling said dispenser
US3154075A (en) * 1960-11-02 1964-10-27 Norwich Pharma Co Vaginal applicator
US3261695A (en) * 1962-12-24 1966-07-19 Gen Foods Corp Process for preparing dehydrated foods
US3330730A (en) * 1962-08-03 1967-07-11 Colgate Palmolive Co Pressurized emulsion quick breaking foam compositions
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US3244589A (en) * 1962-10-26 1966-04-05 Sunnen Alkyl phenoxy polyethoxy ether spermicidal aerosol
US3298919A (en) * 1962-12-26 1967-01-17 Dow Corning Shaving cream containing polysiloxanes
US3149543A (en) * 1963-03-04 1964-09-22 Ingersoll Rand Co Non-lubricated piston
GB1026831A (en) * 1963-05-31 1966-04-20 Mediline Ag Preparations for use in feminine hygiene
US3333333A (en) * 1963-08-14 1967-08-01 Rca Corp Method of making magnetic material with pattern of embedded non-magnetic material
US3236457A (en) * 1963-08-21 1966-02-22 John R Kennedy Composite spray container assembly
US3263867A (en) * 1963-12-26 1966-08-02 Valve Corp Of America Metering button-type aerosol actuator
US3395214A (en) * 1964-01-09 1968-07-30 Scholl Mfg Co Inc Antiperspirant composition providing a readily collapsible sprayable foam
GB1052724A (en) * 1964-04-27
US3303970A (en) * 1964-07-14 1967-02-14 Jerome Marrow Device for simultaneously dispensing from plural sources
US3395215A (en) * 1964-10-15 1968-07-30 Colgate Palmolive Co Pressurized lotion composition
US3384541A (en) * 1964-10-28 1968-05-21 William G. Clark Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants
US3263869A (en) * 1964-11-03 1966-08-02 Calmar Inc Liquid dispenser with overcap
US3419658A (en) * 1965-01-25 1968-12-31 Du Pont Nonaqueous aerosol foams containing mineral oil
US3346451A (en) * 1965-01-27 1967-10-10 S E Massengill Company Concentrated liquid lactic acid douche preparation containing aromatics
US3301444A (en) * 1965-08-12 1967-01-31 Oel Inc Aerosol metering valve
US3456052A (en) * 1965-09-28 1969-07-15 Garrett Lab Inc Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol
US3401849A (en) * 1966-05-24 1968-09-17 Robert L. Weber Low force metering valve
US3377004A (en) * 1966-10-03 1968-04-09 Gen Mills Inc Metered dispensing container
US3527559A (en) * 1967-01-05 1970-09-08 Standard Pharmacal Corp Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent
US3366494A (en) * 1967-02-15 1968-01-30 Du Pont Pressurized aerosol food emulsions
US3561262A (en) * 1967-10-26 1971-02-09 Magnaflux Corp Water soluble developer
US3540448A (en) * 1968-01-17 1970-11-17 Joseph Sunnen Rechargeable applicator for dispensing substances in a foam condition
US3563098A (en) * 1968-06-28 1971-02-16 Rex Chainbelt Inc Automatic quick release mechanism
US3559890A (en) * 1968-09-03 1971-02-02 William R Brooks Foam dispenser
FR1601438A (en) 1968-10-17 1970-08-24
US3667461A (en) * 1968-11-05 1972-06-06 Paul A Zamarra Disposable syringe
US3819524A (en) * 1969-06-17 1974-06-25 Colgate Palmolive Co Cosmetic composition for thermal dispensing
US3577518A (en) * 1969-07-18 1971-05-04 Nat Patent Dev Corp Hydrophilic hairspray and hair setting preparations
US3787566A (en) * 1969-07-29 1974-01-22 Holliston Labor Inc Disinfecting aerosol compositions
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3770648A (en) * 1971-07-12 1973-11-06 Bristol Myers Co Anhydrous aerosol foam
US3751562A (en) * 1972-09-22 1973-08-07 Princeton Biomedix Medicated gelled oils
NO812612L (en) 1980-08-06 1982-02-08 Ferring Pharma Ltd ENZYME inhibitor.
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (en) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk Oligonucleotide derivative and its preparation
FR2540122B1 (en) 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2575751B1 (en) 1985-01-08 1987-04-03 Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
DE3681787D1 (en) 1985-07-05 1991-11-07 Whitehead Biomedical Inst EXPRESSION OF FOREIGN GENETIC MATERIAL IN EPITHELIC CELLS.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (en) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd Poly-labeled oligonucleotide derivative
US5834185A (en) 1986-10-28 1998-11-10 Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE3851889T2 (en) 1987-06-24 1995-04-13 Florey Howard Inst NUCLEOSIDE DERIVATIVES.
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (en) 1987-11-12 1989-05-24 Max Planck Gesellschaft MODIFIED OLIGONUCLEOTIDS
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
JPH03503894A (en) 1988-03-25 1991-08-29 ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション Oligonucleotide N-alkylphosphoramidate
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
EP0497875B1 (en) 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
JP2507895B2 (en) 1989-12-19 1996-06-19 工業技術院長 New synthesis system of ribozyme
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5084824A (en) 1990-03-29 1992-01-28 National Semiconductor Corporation Simulation model generation from a physical data base of a combinatorial circuit
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (en) 1990-05-11 1998-08-01 Microprobe Corp SOLID SUPPORTS FOR NUCLEIC ACID HYBRIDIZATION TESTS AND METHODS TO IMMOBILIZE OLIGONUCLEOTIDES IN A COVALENT WAY.
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5846713A (en) 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5780228A (en) 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5723289A (en) 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5869641A (en) 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
DE69126530T2 (en) 1990-07-27 1998-02-05 Isis Pharmaceuticals Inc NUCLEASE RESISTANT, PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULE GENE EXPRESSION
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
EP0541722B1 (en) 1990-08-03 1995-12-20 Sterling Winthrop Inc. Compounds and methods for inhibiting gene expression
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
WO1992008728A1 (en) 1990-11-08 1992-05-29 Hybridon, Inc. Incorporation of multiple reporter groups on synthetic oligonucleotides
DE69130831T2 (en) 1990-11-21 1999-09-16 Iterex Pharma Lp SYNTHESIS OF EQUIMOLAR MIXTURES OF VARIOUS OLIGOMERS, SPECIALLY OLIGOPEPTIDE MIXTURES
US5683874A (en) 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US6028186A (en) 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5449754A (en) 1991-08-07 1995-09-12 H & N Instruments, Inc. Generation of combinatorial libraries
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE59208572D1 (en) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclic nucleosides, oligonucleotides, processes for their preparation and intermediates
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
WO1993009668A1 (en) 1991-11-22 1993-05-27 Affymax Technology N.V. Combinatorial strategies for polymer synthesis
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
ATE226093T1 (en) 1991-11-26 2002-11-15 Isis Pharmaceuticals Inc INCREASED FORMATION OF TRIPLE AND DOUBLE HELICES FROM OLIGOMERS WITH MODIFIED PYRIMIDINES
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
FR2687679B1 (en) 1992-02-05 1994-10-28 Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
DE69303712T2 (en) 1992-04-28 1997-02-20 Univ Yale TARGETED CUTTING OF RNA BY MEANS OF EUKARYONTIC RNASE P AND EXTERNAL LEADING SEQUENCE
US5989906A (en) 1992-05-14 1999-11-23 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
US5972699A (en) 1992-05-14 1999-10-26 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting herpes simplex virus replication
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5646020A (en) 1992-05-14 1997-07-08 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes for preferred targets
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US6017756A (en) 1992-05-14 2000-01-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting hepatitis B virus replication
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
CA2139411A1 (en) 1992-07-02 1994-01-20 Eiko Otsuka Ribozyme having a thermodynamically stable loop
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
US5288314A (en) 1992-08-04 1994-02-22 Crescent Manufacturing Polish
US5646042A (en) 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5721099A (en) 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5891684A (en) 1992-10-15 1999-04-06 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
US5811300A (en) 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5612215A (en) 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
EP0682716A4 (en) 1993-01-15 1999-10-27 New York Health Res Inst Rna assays using rna binary probes and ribozyme ligase.
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
ATE155467T1 (en) 1993-03-30 1997-08-15 Sanofi Sa ACYCLIC NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDE SEQUENCES CONTAINING THEM
JPH08508491A (en) 1993-03-31 1996-09-10 スターリング ウインスロップ インコーポレイティド Oligonucleotides with phosphodiester bonds replaced by amide bonds
DE4311944A1 (en) 1993-04-10 1994-10-13 Degussa Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
DE69425890D1 (en) 1993-06-04 2000-10-19 Us Health METHOD FOR TREATING KAPOSI SARCOMA WITH ANTISENSE OLIGONUCLEOTIDES
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
DK0748382T3 (en) 1993-09-02 2003-02-17 Ribozyme Pharm Inc Enzymatic nucleic acid containing non-nucleotide
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5712146A (en) 1993-09-20 1998-01-27 The Leland Stanford Junior University Recombinant combinatorial genetic library for the production of novel polyketides
CN1154640C (en) 1993-10-01 2004-06-23 纽约市哥伦比亚大学理事 Complex combinatorial chemical libraries encoded with tags
US5861288A (en) 1993-10-18 1999-01-19 Ribozyme Pharmaceuticals, Inc. Catalytic DNA
US5616466A (en) 1993-11-05 1997-04-01 Cantor; Glenn H. Ribozyme-mediated inhibition of bovine leukemia virus
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5712384A (en) 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
BR9506535A (en) 1994-01-20 1997-09-16 British Biotech Pharm Metalloproteinase inhibitors
US5683899A (en) 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
US5639647A (en) 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
ES2199247T3 (en) 1994-03-11 2004-02-16 Pharmacopeia Drug Discovery, Inc. DERIVATIVES OF SULFONAMIDE AND ITS USE.
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
DE69519225T2 (en) 1994-03-23 2001-03-29 Univ Penn State Res Found METHOD FOR DETECTING CONNECTIONS FROM A CONNECTIVE LIBRARY.
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
JPH09511828A (en) 1994-04-05 1997-11-25 ファーマジェニクス，インコーポレイテッド Identification and identification of active compounds in compound libraries
US6017768A (en) 1994-05-06 2000-01-25 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5580967A (en) 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
US5595873A (en) 1994-05-13 1997-01-21 The Scripps Research Institute T. thermophila group I introns that cleave amide bonds
US5683902A (en) 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5650316A (en) 1994-06-06 1997-07-22 Research Development Foundation Uses of triplex forming oligonucleotides for the treatment of human diseases
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5998193A (en) 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US5633133A (en) 1994-07-14 1997-05-27 Long; David M. Ligation with hammerhead ribozymes
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5939268A (en) 1994-07-26 1999-08-17 The Scripps Research Institute Combinatorial libraries of molecules and methods for producing same
JPH10503934A (en) 1994-08-09 1998-04-14 ノバルティス アクチエンゲゼルシャフト Antitumor antisense oligonucleotide
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5688670A (en) 1994-09-01 1997-11-18 The General Hospital Corporation Self-modifying RNA molecules and methods of making
US5989908A (en) 1994-09-12 1999-11-23 City Of Hope Modulation of drug and radiation resistant genes
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
JPH08113591A (en) 1994-10-14 1996-05-07 Taiho Yakuhin Kogyo Kk Oligonucleotide and carcinostatic agent containing the same as active ingredient
US6045671A (en) 1994-10-18 2000-04-04 Symyx Technologies, Inc. Systems and methods for the combinatorial synthesis of novel materials
US6004617A (en) 1994-10-18 1999-12-21 The Regents Of The University Of California Combinatorial synthesis of novel materials
US5985356A (en) 1994-10-18 1999-11-16 The Regents Of The University Of California Combinatorial synthesis of novel materials
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5603351A (en) 1995-06-07 1997-02-18 David Sarnoff Research Center, Inc. Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device
US5619680A (en) 1994-11-25 1997-04-08 Berkovich; Semyon Methods and apparatus for concurrent execution of serial computing instructions using combinatorial architecture for program partitioning
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5688696A (en) 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
US5683873A (en) 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5627210A (en) 1995-02-06 1997-05-06 Chiron Corporation Branched combinatorial libraries
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
US5958702A (en) 1995-02-06 1999-09-28 Benner; Steven Albert Receptor-assisted combinatorial chemistry
IT1275862B1 (en) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche ANTI-SENSE TRANSCRIPT ASSOCIATED WITH SOME TYPES OF TUMOR CELLS AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL IN DIAGNOSIS AND TREATMENT
US5770715A (en) 1995-03-22 1998-06-23 Toagosei Co., Ltd. Hammerhead-like nucleic acid analogues and their synthesis
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5807754A (en) 1995-05-11 1998-09-15 Arqule, Inc. Combinatorial synthesis and high-throughput screening of a Rev-inhibiting arylidenediamide array
US5646031A (en) 1995-05-16 1997-07-08 Northern Illinois University SArMV and sCYMVI hairpin ribozymes
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5891737A (en) 1995-06-07 1999-04-06 Zymogenetics, Inc. Combinatorial non-peptide libraries
US5646285A (en) 1995-06-07 1997-07-08 Zymogenetics, Inc. Combinatorial non-peptide libraries
US5910408A (en) 1995-06-07 1999-06-08 The General Hospital Corporation Catalytic DNA having ligase activity
US5693773A (en) 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
EP0833944B1 (en) 1995-06-07 2009-01-07 Gilead Sciences, Inc. Nucleic acid ligands that bind to and inhibit dna polymerases
WO1996040157A1 (en) * 1995-06-07 1996-12-19 Gen-Probe Incorporated USE OF ANTISENSE OLIGONUCLEOTIDES TO IL-6 RECEPTOR mRNA TO INHIBIT CELLULAR PROLIFERATION
DK0839152T3 (en) 1995-06-21 2002-07-08 Martek Biosciences Corp Combinatorial libraries of labeled biochemical compounds and processes for their preparation
US5962337A (en) 1995-06-29 1999-10-05 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US5834588A (en) 1995-07-14 1998-11-10 Yale University (Cyanomethylene) phosphoranes as carbonyl 1,1-dipole synthons for use in constructing combinatorial libraries
NO953680D0 (en) 1995-09-18 1995-09-18 Hans Prydz Cell cycle Enzymes
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
AU7572096A (en) 1995-11-14 1997-06-05 Vimrx Holdings, Ltd. Chimeric oligomers having an rna-cleavage activity
SK66098A3 (en) 1995-11-21 1998-11-04 Icn Pharmaceuticals Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6031071A (en) 1996-01-24 2000-02-29 Biophage, Inc. Methods of generating novel peptides
AU708535B2 (en) 1996-02-15 1999-08-05 Cleveland Clinic Foundation, The RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5880972A (en) 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US5877162A (en) 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US5847150A (en) 1996-04-24 1998-12-08 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 2-methylene-2, 3-dihydrothiazoles and of arrays of substituted 2-methylene-2, 3-dihydrothiazoles
GB9610813D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of benzufuran derivatives
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US5792431A (en) 1996-05-30 1998-08-11 Smithkline Beecham Corporation Multi-reactor synthesizer and method for combinatorial chemistry
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US5840500A (en) 1996-07-11 1998-11-24 Trega Biosciences, Inc. Quinoline derivatives and quinoline combinatorial libraries
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
DE19631178C1 (en) 1996-08-02 1997-08-21 Siemens Ag Inspecting corrosion of carbon steel
EP0960191A4 (en) * 1996-08-22 2003-07-23 Univ Pennsylvania Compositions and methods for use of defensin
AU4153497A (en) 1996-08-26 1998-03-19 Eli Lilly And Company Combinatorial process for preparing substituted thiophene libraries
US5886126A (en) 1996-08-28 1999-03-23 University Of South Florida Combinatorial method of forming cascade polymer surfaces
US5886127A (en) 1996-08-28 1999-03-23 University Of South Florida Combinatorial method of forming cascade polymer surfaces
US5877214A (en) 1996-09-12 1999-03-02 Merck & Co., Inc. Polyaryl-poly(ethylene glycol) supports for solution-phase combinatorial synthesis
DE19639937C1 (en) 1996-09-27 1998-03-12 Siemens Ag Circuit arrangement with combinatorial blocks arranged between registers
US5916899A (en) 1996-10-18 1999-06-29 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5874566A (en) 1996-10-25 1999-02-23 Hisamitsu Pharmaceutical Co. Inc. Il-15 triplex oligonucleotides
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6025371A (en) 1996-10-28 2000-02-15 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US5945070A (en) 1996-10-31 1999-08-31 Merck & Co., Inc. Reaction vessel filter for combinatorial chemistry or biological use
US5972719A (en) 1996-11-05 1999-10-26 Pharmacopeia, Inc. Combinatorial hydroxy-amino acid amide libraries
US5965719A (en) 1996-11-15 1999-10-12 Sunsorb Biotech, Inc. Combinatorial synthesis of carbohydrate libraries
US5856107A (en) 1997-02-04 1999-01-05 Trega Biosciences, Inc. Combinatorial libraries of imidazol-pyrido-indole and imidazol-pyrido-benzothiophene derivatives, methods of making the libraries and compounds therein
US5859190A (en) 1997-02-04 1999-01-12 Trega Biosciences, Inc. Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein
US5925527A (en) 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
US6045755A (en) 1997-03-10 2000-04-04 Trega Biosciences,, Inc. Apparatus and method for combinatorial chemistry synthesis
US5976894A (en) 1997-04-14 1999-11-02 Pharmacopeia, Inc. Combinatorial amide alcohol libraries
US5948696A (en) 1997-06-16 1999-09-07 Pharmacopeia, Inc. Combinatorial biaryl amino acid amide libraries
US6300483B1 (en) 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs
WO1998058058A1 (en) 1997-06-19 1998-12-23 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes with extended cleavage rule
JPH1142091A (en) 1997-07-25 1999-02-16 Toagosei Co Ltd Anti-sense nucleic acid compound
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6008321A (en) 1998-03-16 1999-12-28 Pharmacopeia, Inc. Universal linker for combinatorial synthesis
EP1084273A1 (en) 1998-06-06 2001-03-21 Genostic Pharma Limited Probes used for genetic profiling
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6699973B1 (en) 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
US20030092657A1 (en) * 1999-12-22 2003-05-15 Paul Goodyer Modulation of PAX-2 for controlled apoptosis or survival of cells
CA2394589A1 (en) * 1999-12-22 2001-06-28 Mcgill University Modulation of pax-2 for controlled apoptosis or survival of cells
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7294504B1 (en) * 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
ATE416183T1 (en) * 2002-02-01 2008-12-15 Univ Mcgill OLIGONUCLEOTIDES WITH ALTERNATE SEGMENTS AND USES THEREOF
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
AU2003287366A1 (en) 2002-10-31 2004-06-07 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
EP2284266B1 (en) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US20060135422A1 (en) 2003-04-17 2006-06-22 Moskowitz David W Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
EP1781689A4 (en) * 2004-06-24 2010-11-10 Inst Medical W & E Hall Conjugates and therapeutic uses thereof
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
EP1853242A4 (en) 2005-02-25 2009-11-18 Univ Michigan Small molecule inhibitors of stat3 and the uses thereof
US20070166728A1 (en) 2005-07-22 2007-07-19 Alphagenics, Inc. Genetic profile imaging and data-sharing device and methodology for socially relevant traits

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142320A1 (en) * 1999-02-20 2002-10-03 Ogden Christopher William Diagnosis and treatment of prostate cancer
US20050095257A1 (en) * 2000-09-15 2005-05-05 Kwak Larry W. Defensin-antigen fusion proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHECK E.: "RNA to the rescue?", NATURE PUBLISHING GROUP, September 2003 (2003-09-01), pages 10 - 12, XP002978289 *
DAVIES J. ET AL.: "Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation", HUMAN MOLECULAR GENETICS, vol. 13, no. 2, November 2003 (2003-11-01), pages 235 - 246, XP002990111 *
DONALD C.D. ET AL.: "Cancer-Specific Loss of beta-Defensin 1 in Renal and Prostatic Carcinomas", LABORATORY INVESTIGATION, vol. 83, no. 4, April 2003 (2003-04-01), pages 501 - 505, XP003014319 *
KHOUBEHI ET AL.: "Expression of the developmental and oncogenic Pax2 gene in Human Prostate Cancer", JOURNAL OF UROLOGY, vol. 165, June 2001 (2001-06-01), pages 2115 - 2120, XP005544918 *

Also Published As

Publication number Publication date
US20100196450A1 (en) 2010-08-05
US20110177075A1 (en) 2011-07-21
EP1934331A4 (en) 2009-01-21
EP2392645A1 (en) 2011-12-07
US20110236403A1 (en) 2011-09-29
US7964577B2 (en) 2011-06-21
EP2392646A1 (en) 2011-12-07
US20110178162A1 (en) 2011-07-21
AU2006304321A2 (en) 2008-11-13
US8318692B2 (en) 2012-11-27
EP2402435A3 (en) 2012-03-28
US8735365B2 (en) 2014-05-27
US8431546B2 (en) 2013-04-30
US20110177100A1 (en) 2011-07-21
US20110177101A1 (en) 2011-07-21
CA2625891A1 (en) 2007-04-26
EP2392647A1 (en) 2011-12-07
EP2402435A2 (en) 2012-01-04
WO2007047512A2 (en) 2007-04-26
AU2006304321A1 (en) 2007-04-26
EP2189522A1 (en) 2010-05-26
EP1934331A2 (en) 2008-06-25
AU2006304321B2 (en) 2012-10-04
EP2395076A1 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
WO2007047512A3 (en) Inhibition of pax2 by defb1 induction as a therapy for cancer
EP2146739A4 (en) Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
WO2010040112A3 (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2008054585A3 (en) Use of pegylated il-10 to treat cancer
WO2006138511A3 (en) Use of hif 1alfa modulators for treatment of cancer
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2012005550A3 (en) Pharmaceutical composition for treating gallbladder carcinoma, and method for inhibiting growth and metastasis of gallbladder carcinoma and treating gallbladder carcinoma, using same
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
EP2121002A4 (en) Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
WO2011020061A3 (en) Compositions and methods of for treating bipolar disorder
BR112014028787A2 (en) Non-Small Cell Lung Cancer Treatment Method
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2010135329A3 (en) Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
WO2009074827A3 (en) Combination comprising a mek inhibitor and an aurora kinase inhibitor
WO2010032011A8 (en) Anti-fungal therapy
JP2014521342A5 (en)
WO2009127414A3 (en) Inhibition of angiogenesis and tumor metastasis
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
WO2007101148A3 (en) Hexose compounds to treat cancer
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
MX2013010524A (en) Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2625891

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006304321

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006816925

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006304321

Country of ref document: AU

Date of ref document: 20061016

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12090191

Country of ref document: US